Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Stipple Bio logo — Illuminating the Hidden Targets of Cancer

Stipple Bio

Illuminating the Hidden Targets of Cancer

Founded 2022 United States Cambridge, United States 13 employees

General Information

Company Name Stipple Bio
Founded Year 2022
Location United States Cambridge, United States +1
Employees 13
Social

Get notified when Stipple Bio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Stipple Bio is strategically accelerating its precision oncology pipeline through a multi-target licensing agreement with Lonza, a significant partnership that validates its Pointillist Platform and aims to scale the development of next-generation ADC therapies. This key collaboration, coupled with active hiring for new positions, signals an aggressive expansion of operational capacity and a clear focus on advancing its innovative approach to cancer targeting. These moves position the company for significant pipeline progression and potential market impact.

Signal Types
Partnership Hiring
Strategic Labels
Strategic Partnership Pipeline Acceleration Team Growth
Next Move: Development
·
Impact: 9/10
·
Ideal For: Oncology Biotech VCs - Growth Stage

About Stipple Bio

Stipple Bio, founded in 2022 by cancer biology experts Aaron Ring and Aashish Manglik, is positioning itself at the forefront of oncology therapeutics. This biotechnology company is leveraging its proprietary Pointillist Platform to enhance precision in cancer therapy. By targeting tumor-specific cell surface epitopes with greater accuracy, Stipple Bio aims to improve therapeutic indices and explore targets that are challenging with conventional methods.

The company's flagship candidate, the ADC STP-100, exemplifies this novel epitope-targeting strategy. Backed by investments co-led by RA Capital, a16z Bio+Health, and Nextech Invest, with support from Emerson Collective Investments, GV, LoLa Capital Partners, and GordonMD Global Investments, Stipple Bio is poised to significantly impact the oncology drug discovery landscape. Their mission is to develop next-generation therapeutics that could dramatically improve the lives of cancer patients worldwide.

Taxonomy: Epitope-Targeting, Cancer Therapies, Pointillist Platform, Precision Oncology, ADC Development, Tumor-Specific Targeting, Therapeutic Index Improvement, Translational Science, Oncology Drug Discovery, Chemical Biology, Tumor Immunology, Platform Biotechnology, Early-Stage Oncology, Life-Changing Medicines

Services & Products

Development of targeted cancer medicines
Epitope mapping for oncology
Advanced therapeutic discovery

Target Customers

Cancer patients Healthcare providers Oncology researchers

No funding data available for Stipple Bio yet.

Get notified when Stipple Bio raises funding

Stipple Bio Alternatives & Competitors

Stipple Bio vs
Tessellate Bio
Tessellate Bio The Netherlands

Redefining Synthetic Lethality beyond HRD

Seed
24 employees
Biotechnology
Stipple Bio vs
Massive Bio
Massive Bio Turkey

AI-driven system connecting cancer patients to clinical trials in real time. Industrializing the onc...

Series B
99 employees
AI, Big Data
Stipple Bio vs
Orakl Oncology
Orakl Oncology France

Biology x AI-powered drug development platform to transform precision oncology.

Seed
16 employees

FAQ About Stipple Bio

Illuminating the Hidden Targets of Cancer
Stipple Bio was founded in 2022.
Stipple Bio is headquartered in Cambridge, United States.
Stipple Bio has approximately 13 employees.
Stipple Bio offers: Development of targeted cancer medicines, Epitope mapping for oncology, Advanced therapeutic discovery.
Top alternatives and competitors to Stipple Bio include Tessellate Bio, Massive Bio, Orakl Oncology, Radionetics Oncology, Amphivena Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Stipple Bio and Tessellate Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Stipple Bio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy